[{"orgOrder":0,"company":"Nusano","sponsor":"Cellectar","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2025","type":"Agreement","leadProduct":"CLR 125","moa":"Ionising radiation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Nusano","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nusano \/ Cellectar","highestDevelopmentStatusID":"5","companyTruncated":"Nusano \/ Cellectar"},{"orgOrder":0,"company":"Nusano","sponsor":"Starget Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Agreement","leadProduct":"DOTA-PTR-58","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Nusano","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nusano \/ Starget Pharma","highestDevelopmentStatusID":"5","companyTruncated":"Nusano \/ Starget Pharma"},{"orgOrder":0,"company":"Nusano","sponsor":"Glytherix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Agreement","leadProduct":"177-Lu","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Nusano","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nusano \/ Glytherix","highestDevelopmentStatusID":"4","companyTruncated":"Nusano \/ Glytherix"},{"orgOrder":0,"company":"Nusano","sponsor":"PharmaLogic","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Nusano","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nusano \/ PharmaLogic","highestDevelopmentStatusID":"1","companyTruncated":"Nusano \/ PharmaLogic"},{"orgOrder":0,"company":"Nusano","sponsor":"Clarity Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2025","type":"Agreement","leadProduct":"67Cu-SAR-bisPSMA","moa":"Glutamate carboxypeptidase II (GCPII)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nusano","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nusano \/ Clarity Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Nusano \/ Clarity Pharmaceuticals"}]